Effect of Combining Therapy with Traditional Chinese Medicine-Based Psychotherapy and Herbal Medicines in Women with Menopausal Syndrome: A Randomized Controlled Clinical Trial
Table 3
Difference in adjusted mean change of MENQOL and its subscales score between interventions and placebo group*.
Subscales
Time/weeks
PSY + CHM versus Placebo
PSY versus Placebo
CHM versus Placebo
CHM + PSY versus PSY
CHM versus CHM + PSY
CHM versus PSY
Difference in mean change (95% CI)
value
adjust
Difference in mean change (95% CI)
value
adjust
Difference in mean change (95% CI)
value
adjust
Difference in mean change (95% CI)
value
adjust
Difference in mean change (95% CI)
value
adjust
Difference in mean change (95% CI)
value
adjust
12
−1.08
0.6044
1
1.49
0.4704
1
−1.89
0.3551
1
−2.57
0.2171
1
−0.81
0.6933
1
−3.39
0.0982
1
(−8.14–5.98)
(−5.52–8.51)
(−8.82–5.04)
(−9.64–4.49)
(−7.79–6.17)
(−10.32–3.54)
Vasomotor
24
−1.74
0.4188
1
1.32
0.5413
1
1.92
0.3625
1
−3.06
0.1561
1
3.66
0.0816
1
0.59
0.7780
1
(−9.04–5.56)
(−6.01–8.66)
(−5.21–9.05)
(−10.37–4.25)
(−3.45–10.76)
(−6.55–7.74)
Over all time points
0.21
0.8851
1
1.98
0.1628
0.9771
0.48
0.7322
1
−1.78
0.2114
1
0.27
0.8456
1
−1.51
0.2808
1
(−3.56–3.97)
(−1.78–5.74)
(−3.22–4.17)
(−5.54–1.99)
(−3.43–3.97)
(−5.2–2.19)
12
0.95
0.7936
1
4.85
0.1825
1
−3.57
0.3188
1
−3.89
0.2860
1
−4.53
0.2086
1
−8.42
0.0192*
1
(−11.41–13.32)
(−7.47–17.17)
(−15.73–8.58)
(−16.26–8.47)
(−16.73–7.67)
(−20.58–3.73)
Psychosocial
24
6.06
0.0992
1
3.88
0.2919
1
−0.24
0.9471
1
2.18
0.5527
1
−6.3
0.0799
1
−4.12
0.2530
1
(−6.38–18.5)
(−8.59–16.34)
(−12.42–11.94)
(−10.27–14.64)
(−18.47–5.87)
(−16.31–8.08)
Over all time points
4.35
0.1517
0.9103
5.01
0.0984
0.5907
−2.07
0.4876
1
−0.67
0.8261
1
−6.42
0.0318
0.1910
−7.08
0.0179
0.1073
(−3.68–12.38)
(−3.01–13.04)
(−9.97–5.83)
(−8.69–7.36)
(−14.32–1.48)
(−14.98–0.81)
12
−8.63
0.1967
1
−5.65
0.3962
1
−11.03
0.0936
1
−2.98
0.6552
1
−2.39
0.7163
1
−5.38
0.4129
1
(−31.28–14.02)
(−28.21–16.91)
(−33.28–11.23)
(−25.63–19.66)
(−24.74–19.95)
(−27.63–16.88)
Physical
24
7.73
0.2595
1
5.57
0.4184
1
−3
0.6542
1
2.17
0.7523
1
−10.74
0.1092
1
−8.57
0.2025
1
(−15.5–30.96)
(−17.75–28.88)
(−25.74–19.73)
(−21.1–25.43)
(−33.43–11.96)
(−31.35–14.21)
Over all time points
−1.4
0.7987
1
0.62
0.9101
1
−5.38
0.3193
1
−2.02
0.713
1
−3.98
0.4611
1
−6
0.2669
1
(−15.94–13.14)
(−13.93–15.17)
(−19.69–8.93)
(−16.57–12.53)
(−18.29–10.33)
(−20.31–8.31)
12
0.14
0.9489
1
−1.46
0.5146
1
−2.88
0.1921
1
1.6
0.4736
1
−3.02
0.1704
1
−1.42
0.5181
1
(−7.46–7.75)
(−9.05–6.13)
(−10.36–4.6)
(−5.98–9.19)
(−10.49–4.45)
(−8.87–6.03)
Sexual
24
1.02
0.6568
1
0.61
0.7915
1
−1.45
0.5175
1
0.41
0.8578
1
−2.47
0.2683
1
−2.06
0.3578
1
(−6.74–8.78)
(−7.18–8.4)
(−9.05–6.15)
(−7.34–8.15)
(−10.02–5.09)
(−9.65–5.53)
Over all time points
0.63
0.7404
1
−0.3
0.8753
1
−1.87
0.3176
1
0.93
0.6239
1
−2.51
0.1795
1
−1.58
0.399
1
(−4.41–5.68)
(−5.35–4.75)
(−6.84–3.09)
(−4.09–5.96)
(−7.44–2.43)
(−6.52–3.37)
12
−8.18
0.4723
1
−1.1
0.9225
1
−18.85
0.0924
1
−7.08
0.5327
1
−10.67
0.3397
1
−17.74
0.1118
1
(−46.75–30.39)
(−39.59–37.38)
(−56.76–19.06)
(−45.52–31.37)
(−48.54–27.2)
(−55.52–20.04)
QOL
24
13.88
0.2295
1
11.58
0.3175
1
−2.08
0.8540
1
2.3
0.8415
1
−15.96
0.1565
1
−13.66
0.2266
1
(−25.25–53.02)
(−27.67–50.82)
(−40.42–36.26)
(−36.76–41.37)
(−54.12–22.19)
(−51.93–24.61)
Over all time points
4.07
0.6629
1
7.14
0.4444
1
−8.58
0.3502
1
−3.07
0.7408
1
−12.64
0.1668
1
−15.72
0.0861
0.5165
(−20.64–28.77)
(−17.58–31.86)
(−32.89–15.73)
(−27.69–21.54)
(−36.84–11.56)
(−39.93–8.5)
*. *All analyses were conducted on the data adjusted for age (continuous), body mass index (kg/m2, continuous), menopausal status (menopause transition versus postmenopausal). Estimates of difference in mean change from baseline versus placebo, along with values and 95% CIs, from mixed-model analysis that used data from baseline and all follow-up time points (total, for adjusted analyses).
